Información del artículo
Resumen
El incremento de la frecuencia y morbimortalidad de las infecciones fúngicas ha hecho necesaria la disponibilidad de nuevos antifúngicos. Candida spp. y Aspergillus spp. son los agentes más frecuentemente productores de micosis graves en pacientes críticos e inmunodeprimidos, pero otros hongos emergentes deben ser considerados. El uso racional y precoz de los antifúngicos debe combinar procedimientos diagnósticos microbiológicos y de imagen. En la medida que las nuevas opciones terapéuticas suponen un avance su complejidad también ha aumentado. En los últimos años, 3 nuevos antifúngicos (micafungina, anidulafungina y posaconazol) se han añadido al armamento terapéutico de estas infecciones. Este artículo incluye una actualización, a la luz de las últimas evidencias científicas, de la eficacia clínica, farmacocinética, seguridad y dosificación de los diferentes antifúngicos disponibles en la actualidad para el tratamiento de las infecciones por Candida spp., Aspergillus spp., Cryptococcus spp., zygomycetos, Scedosporium spp. y Fusarium spp.
Palabras clave:
Tratamiento antifúngico
Actualización
Infección fúngica invasiva
Abstract
Increases in the rates of fungal infections, as well as their associated morbidity and mortality has led to a need for additional antifungal agents. The most common serious fungal agents in immunosuppressed and critically ill patients are Candida spp. and Aspergillus spp., although other emerging fungi must be considered. Rational, early systemic antifungal treatment should be based on diagnostic imaging techniques and conventional mycological and non-culture-based procedures. While the availability of new therapeutic options is an important advance, antifungal therapy has become increasingly complex. In addition to the available antifungal armamentarium, recent research has resulted in the introduction of three new antifungal agents: micafungin, anidulafungin, and posaconazole. This article provides an update, based on the latest scientific evidence, of the clinical efficacy, pharmacokinetics, safety and dosing of antifungal drugs administered in the management of Candida spp., Aspergillus spp., Cryptococcus spp., Zygomycetes, Scedosporium spp. and Fusarium spp.
Keywords:
Antifungal therapy
Update
Invasive fungal infections
El Texto completo está disponible en PDF
Bibliografía
[1.]
D. Neofytos, D. Horn, E. Anaissie, W. Steinbach, A. Olyaei, J. Fishman, et al.
Epidemiology and outcome of invasive fungal infection in adult haematopoietic stem cell transplant recipients: analysis of multicentre Prospective Antifungal Therapy (PATH) Alliance registry.
Clin Infect Dis, 48 (2009), pp. 265-273
[2.]
P.G. Pappas, B.D. Alexander, D.R. Andes, S. Hadley, C.A. Kauffman, A. Freifeld, et al.
Invasive fungal infections among organ transplant recipients: results of the transplant-associated infection surveillance network (TRANSNET).
Clin Infect Dis, 50 (2010), pp. 1101-1111
[3.]
M.D. Zilberberg, A.F. Shorr, M.H. Kollef.
Secular trends in candidemia-related hospitalization in the United States, 2000–2005.
Infect Control Hosp Epidemiol, 29 (2008), pp. 978-980
[4.]
O. Leroy, J.-P. Gangneux, P. Montravers, J.-P. Mira, F. Gouin, J. Sollet, AmarCand Study Group: Epidemiology, management, and risk factors for death of invasive, et al.
Candida infections in critical care: a multicenter, prospective, observational study in France (2005–2006).
Crit Care Med, 37 (2009), pp. 1612-1618
[5.]
K.W. Garey, M. Rege, M.P. Pai, D.E. Mingo, K.J. Suda, R.S. Turpin, et al.
Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multiinstitutional study.
Clin Infect Dis, 43 (2006), pp. 25-31
[6.]
J.M. Aguado, I. Ruiz-Camps, P. Muñoz, J. Mensa, B. Almirante, L. Vázquez, Grupo de Estudio de Micología Médica de la SEIMC (GEMICOMED), et al.
Guidelines for the treatment of invasive candidiasis and other yeasts. Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC). 2010 Update.
Enferm Infecc Microbiol Clin, 29 (2011), pp. 345-361
[7.]
P.G. Pappas, C.A. Kauffman, D. Andes, D.K. Benjamin, T.F. Calandra, J.E. Edwards, et al.
Clinical practice guidelines for the management of candidiasis: 2009 Update by the Infectious Diseases Society of America.
Clin Infect Dis, 48 (2009), pp. 503-535
[8.]
I. Lee, N.O. Fishman, T.E. Zaoutis, K.H. Morales, M.G. Weiner, M. Synnestvedt, et al.
Risk factors for fluconazole-resistant Candida glabrata bloodstream infections.
Arch Int Med, 169 (2009), pp. 379-383
[9.]
S.S. Magill, C. Shields, C.L. Sears, M. Choti, W.G. Merz.
Triazole Cross-Resistance among Candida spp.: case report, occurrence among bloodstream isolates, and implications for antifungal therapy.
J Clin Microbiol, 44 (2006), pp. 529-535
[10.]
J.H. Rex, J.E. Bennett, A.M. Sugar, P.G. Pappas, C.M. Van der Horst, J.E. Edwards, et al.
A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia.
N Engl J Med, 331 (1994), pp. 1325-1330
[11.]
B.J. Kullberg, J.D. Sobel, M. Ruhnke, P.G. Pappas, C. Viscoli, J.H. Rex, et al.
Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in nonneutropenic patients: a randomised non-inferiority trial.
Lancet, 366 (2005), pp. 1435-1442
[12.]
W.W. Hope, E.M. Billaud, J. Lestner, D.W. Denning.
Therapeutic monitoring for triazoles.
Curr Opin Infect Dis, 21 (2008), pp. 580-586
[13.]
T.J. Walsh, P. Pappas, D.J. Winston, H.M. Lazarus, F. Petersen, J. Raffalli, et al.
Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever.
N Engl J Med, 346 (2002), pp. 225-234
[14.]
J. Mora-Duarte, R. Betts, C. Rotstein, A.L. Colombo, L. Thompson-Moya, J. Smietana, Caspofungin Invasive Candidiasis Study Group, et al.
Comparison of caspofungin and amphotericin B for invasive candidiasis.
N Engl J Med, 347 (2002), pp. 2020-2029
[15.]
E.R. Kuse, P. Chetchotisakd, C.A. Da Cunha, M. Ruhnke, C. Barrios, D. Raghunadharao, Micafungin Invasive Candidiasis Working Group, et al.
Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial.
Lancet, 369 (2007), pp. 1519-1527
[16.]
P.G. Pappas, C.M. Rotstein, R.F. Betts, M. Nucci, D. Talwar, J.J. De Waele, et al.
Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis.
Clin Infect Dis, 45 (2007), pp. 883-893
[17.]
A.C. Reboli, C. Rotstein, P.G. Pappas, S.W. Chapman, D.H. Kett, D. Kumar, Anidulafungin Study Group, et al.
Anidulafungin versus fluconazole for invasive candidiasis.
N Engl J Med, 356 (2007), pp. 2472-2482
[18.]
R.F. Betts, M. Nucci, D. Talwar, M. Gareca, F. Queiroz-Telles, R.J. Bedimo, et al.
A multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis.
Clin Infect Dis, 48 (2009), pp. 1676-1684
[19.]
A.L. Colombo, A.L. Ngai, M. Bourque, S.K. Bradshaw, K.M. Strohmaier, A.F. Taylor, et al.
Caspofungin use in patients with invasive candidiasis caused by common nonalbicans Candida species: review of the caspofungin database.
Antimicrob Agents Chemother, 54 (2010), pp. 1864-1871
[20.]
T.E. Zaoutis, H.S. Jafri, L.M. Huang, F. Locatelli, A. Barzilai, W. Ebell, et al.
A prospective multicenter study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patients.
Pediatrics, 123 (2009), pp. 877-884
[21.]
C. Sanz-Rodríguez, R. Arranz, J.M. Cisneros, P.J. García-Sánchez, M. Jurado, J. López, et al.
Absence of clinically relevant effect of caspofungin oncyclosporin pharmacokinetics.
Swiss Med Wkly, 135 (2005), pp. 658-659
[22.]
M. Winkler, J. Pratschke, U. Schulz, S. Zheng, M. Zhang, W. Li, et al.
Caspofunginfor post solid organ transplant invasive fungal disease: results of a retrospective observational study.
Transpl Infect Dis, 12 (2010), pp. 230-237
[23.]
F. Queiroz-Telles, E. Berezin, G. Leverger, A. Freire, A. Van der Vyver, T. Chotpitaya- Sunondh, et al.
Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial.
Pediatr Infect Dis J, 27 (2008), pp. 820-826
[24.]
M.F. Hebert, R.W. Townsend, S. Austin, G. Balan, D.K. Blough, D. Buell, et al.
Concomitant cyclosporine and micafungin pharmacokinetics in healthy volunteers.
J Clin Pharmacol, 45 (2005), pp. 954-960
[25.]
M.F. Hebert, D.K. Blough, R.W. Townsend, M. Allison, D. Buell, J. Keirns, et al.
Concomitant tacrolimus and micafungin pharmacokinetics in healthy volunteers.
J Clin Pharmacol, 45 (2005), pp. 1018-1024
[26.]
L. Ostrosky-Zeichner, D. Kontoyiannis, J. Raffalli, K.M. Mullane, J. Vázquez, E.J. Anaissie, et al.
International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia.
Eur J Clin Microbiol Infect Dis, 24 (2005), pp. 654-661
[27.]
G.N. Forrest, F. Rasetto, G. Akpek, B. Philosophe.
Safety and efficacy of micafungin in transplantation recipients.
Transplantation, 82 (2006), pp. 1549
[28.]
E. Cateau, M.H. Rodier, C. Imbert.
In vitro efficacies of caspofungin or micafungin catheter lock solutions on Candida albicans biofilm growth.
J Antimicrob Chemother, 62 (2008), pp. 153-155
[29.]
B.D. Brielmaier, E. Casabar, C.M. Kurtzeborn, P.S. McKinnon, D.J. Ritchie.
Early clinical experience with anidulafungin at a large tertiary care medical center.
Pharmacotherapy, 28 (2008), pp. 64-73
[30.]
J.A. Dowell, M. Stogniew, D. Krause, T. Henkel, I.E. Weston.
Assessment of the safety and pharmacokinetics of anidulafungin when administered with cyclosporine.
J Clin Pharmacol, 45 (2005), pp. 227-233
[31.]
J.A. Dowell, M. Stogniew, D. Krause, T. Henkel, B. Damle.
Lack of pharmacokinetici nteraction between anidulafungin and tacrolimus.
J Clin Pharmacol, 47 (2007), pp. 305-314
[32.]
T.J. Walsh, H. Teppler, G.R. Donowitz, J.A. Maertens, L.R. Baden, A. Dmoszynska, et al.
Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia.
N Engl J Med, 351 (2004), pp. 1391-1402
[33.]
G. García-Effron, S. Park, D.S. Perlin.
Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints.
Antimicrob Agents Chemother, 53 (2009), pp. 112-122
[34.]
L. Ostrosky-Zeichner, K.A. Marr, J.H. Rex, S.H. Cohen.
Amphotericin B: time for a new “gold standard”.
Clin Infect Dis, 37 (2003), pp. 415-425
[35.]
K. Hirata, T. Aoyama, Y. Matsumoto, F. Ogawa, H. Yamazaki, A. Kikuti, et al.
Pharmacokinetics of antifungal agent micafungin in critically ill patients receiving continuous hemodialysis filtration.
Yakugaku Zasshi, 127 (2007), pp. 897-901
[36.]
O. Burkhardt, V. Kaever, H. Burhenne, J.T. Kielstein.
Extended daily dialysis does not affect the pharmacokinetics of anidulafungin.
Int J Antimicrob Agents, 34 (2009), pp. 282-283
[37.]
J.L. Wang, C.H. Chang, Y. Young-Xu, K.A. Chan.
Systematic review and meta-analysis of the tolerability and hepatotoxicity ofantifungals in empirical and definitive therapy for invasive fungal infection.
Antimicrob Agents Chemother, 54 (2010), pp. 2409-2419
[38.]
P.E. Verweij, E. Mellado, W.J. Melchers.
Multiple-triazole-resistant aspergillosis.
N Engl J Med, 356 (2007), pp. 1481-1483
[39.]
E. Snelders, R.A. Huis In‘t Veld, A.J. Rijs, G.H. Kema, W.J. Melchers, P.E. Verweij.
Possible environmental origin of resistance of Aspergillus fumigatus to medical triazoles.
Appl Environ Microbiol, 75 (2009), pp. 4053-4057
[40.]
M.C. Arendrup, E. Mavridou, K.L. Mortensen, E. Snelders, M. Frimodt, N. ller, et al.
Development of azole resistance in Aspergillus fumigatus during azole therapy associated with change in virulence.
PLoS One, 5 (2010), pp. e10080
[41.]
T.J. Walsh, E.J. Anaissie, D.W. Denning, R. Herbrecht, D.P. Kontoyiannis, K.A. Marr, et al.
Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America.
Clin Infect Dis, 46 (2008), pp. 327-360
[42.]
J. Fortún, J. Carratalá, J. Gavaldá, M. Lizasoain, M. Salavert, R. De la Cámara, Grupo de Estudio de Micología Médica de la SEIMC (GEMICOMED), et al.
Guidelines for the treatment of invasive fungal disease by Aspergillus spp. and other fungi issued by the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC). 2011 Update.
Enferm Infecc Microbiol Clin, 29 (2011), pp. 435-454
[43.]
R. Herbrecht, D.W. Denning, T.F. Patterson, J.E. Bennett, R.E. Greene, J.W. Oestmann, et al.
Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.
N Engl J Med, 347 (2002), pp. 408-415
[44.]
O.A. Cornely, J. Maertens, M. Bresnik, R. Ebrahimi, A.J. Ullmann, E. Bouza, et al.
Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial).
Clin Infect Dis, 44 (2007), pp. 1289-1297
[45.]
C. Viscoli, R. Herbrecht, H. Akan, L. Baila, A. Sonet, A. Gallamini, et al.
An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients.
J Antimicrob Chemother, 64 (2009), pp. 1274-1281
[46.]
R. Herbrecht, J. Maertens, L. Baila, M. Aoun, W. Heinz, R. Martino, et al.
Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer study.
Bone Marrow Transplant, 45 (2010), pp. 1227-1233
[47.]
J. Maertens, I. Raad, G. Petrikkos, M. Boogaerts, D. Selleslag, F.B. Petrsen, et al.
Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy.
Clin Infect Dis, 39 (2004), pp. 1563-1571
[48.]
T.J. Walsh, I. Raad, T.F. Patterson, P. Chandrasekar, G.R. Donowitz, R. Graybill, et al.
Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial.
Clin Infect Dis, 44 (2007), pp. 2-12
[49.]
D.P. Kontoyiannis, V. Ratanatharathorn, J.A. Young, J. Raymond, M. Laverdiere, D.W. Denning, et al.
Micafungin alone or in combination with other systemic antifungal therapies in hematopoietic stem cell transplant recipients with invasive aspergillosis.
Transpl Infect Dis, 11 (2009), pp. 89-93
[50.]
D. Caillot.
Intravenous itraconazole followed by oral itraconazole for the treatment of amphotericin-B-refractory invasive pulmonary aspergillosis.
Acta Haematol, 109 (2003), pp. 111-118
[51.]
K.A. Marr, M. Boeckh, R.A. Carter, H.W. Kim, L. Corey.
Combination antifungal therapy for invasive aspergillosis.
Clin Infect Dis, 39 (2004), pp. 797-802
[52.]
N. Singh, A.P. Limaye, G. Forrest, N. Safdar, P. Muñoz, K. Pursell, et al.
Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study.
Transplantation, 81 (2006), pp. 320-326
[53.]
D. Caillot, T.A. Thiebaut, R. Herbrecht, S. Botton, A. Pigneux, F. Bernard, et al.
Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (COMBISTRAT trial).
Cancer, 110 (2007), pp. 2740-2746
[54.]
L. Ostrosky-Zeichner.
Combination antifungal therapy: a critical review of the evidence.
Clin Microbiol Infect, 14 (2008), pp. 65-70
[55.]
J. Maertens, O. Marchetti, R. Herbrecht, O.A. Cornely, U. Fluckiger, P. Frere, et al.
European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3-2009 Update.
Bone Marrow Transplant, 46 (2011), pp. 709-718
[56.]
A.H. Saad, D.D. DePestel, P.L. Carver.
Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants.
Pharmacotherapy, 26 (2006), pp. 1730-1744
[57.]
H. Leather, R.M. Boyette, L. Tian, J.R. Wingard.
Pharmacokinetic evaluation of the drug interaction between intravenous itraconazole and intravenous tacrolimus or intravenous cyclosporin A in allogeneic hematopoietic stem cell transplant recipients.
Biol Blood Marrow Transplant, 12 (2006), pp. 325-334
[58.]
A.S. Mathis, N.K. Shah, G.S. Friedman.
Combined use of sirolimus and voriconazole in renal transplantation: a report of two cases.
Transplant Proc, 36 (2004), pp. 2708-2709
[59.]
C.A. Sable, B.Y. Nguyen, J.A. Chodakewitz, M.J. DiNubile.
Safety and tolerability of caspofungin acetate in the treatment of fungal infections.
Transpl Infect Dis, 4 (2002), pp. 25-30
[60.]
P.H. Chandrasekar, J.D. Sobel.
Micafungin: a new echinocandin.
Clin Infect Dis, 42 (2006), pp. 1171-1178
[61.]
P.K. Linden, K. Coley, P. Fontes, J.J. Fung, S. Kusne.
Invasive aspergillosis in liver transplant recipients: outcome comparison of therapy with amphotericin B lipid complex and a historical cohort treated with conventional amphotericin B.
Clin Infect Dis, 37 (2003), pp. 17-25
[62.]
J. Fortun, P. Martín-Dávila, M.A. Sánchez, V. Pintado, M.E. Álvarez, A. Sánchez-Sousa, et al.
Voriconazole in the treatment of invasive mold infections in transplant recipients.
Eur J Clin Microbiol Infect Dis, 22 (2003), pp. 408-413
[63.]
L.R. Baden, J.T. Katz, J.A. Fishman, C. Koziol, A. DelVecchio, M. Doran, et al.
Salvage therapy with voriconazole for invasive fungal infections in patients failing or intolerant to standard antifungal therapy.
Transplantation, 76 (2003), pp. 1632-1637
[64.]
J. Maertens, G. Egerer, W.S. Shin, D. Reichert, M. Stek, S. Chandwani, et al.
Caspofungin use in daily clinical practice for treatment of invasive aspergillosis: results of a prospective observational registry.
BMC Infect Dis, 10 (2010), pp. 182
[65.]
D.W. Denning, K.A. Marr, W.M. Lau, D.P. Facklam, V. Ratanatharathorn, C. Becker, et al.
Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis.
J Infect, 53 (2006), pp. 337-349
[66.]
B.D. Alexander, J.R. Perfect, J.S. Daly, A. Restrepo, A.M. Tobon, H. Patino, et al.
Posaconazole as salvage therapy in patients with invasive fungal infections after solid organ transplant.
Transplantation, 86 (2008), pp. 791-796
[67.]
M.O. Karlsson, I. Lutsar, P.A. Milligan.
Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies.
Antimicrob Agents Chemother, 53 (2009), pp. 935-944
[68.]
A.C. Pasqualotto, D.W. Denning.
New and emerging treatments for fungal infections.
J Antimicrob Chemother, 61 (2008), pp. 19-30
[69.]
T.J. Walsh, I. Lutsar, T. Driscoll, B. Dupont, M. Roden, P. Ghahramani, et al.
Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children.
Pediatr Infect Dis J, 21 (2002), pp. 240-248
[70.]
J.R. Perfect, W.E. Dismukes, F. Dromer, D.L. Goldman, J.R. Graybill, R.J. Hamill, et al.
Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america.
Clin Infect Dis, 50 (2010), pp. 291-322
[71.]
F. Dromer, C. Bernede-Bauduin, D. Guillemot, O. Lortholary, French Cryptococcosis Study Group.
Major role for amphotericin B–flucytosine combination in severe cryptococcosis.
PLoS One, 3 (2008), pp. e2870
[72.]
H.Y. Sun, B.D. Alexander, O. Lortholary, F. Dormer, G.N. Forrestt, G.M. Lyon, et al.
Lipid formulations of amphotericin B significantly improve outcome in solid organ transplant recipients with central nervous system cryptococcosis.
Clin Infect Dis, 49 (2009), pp. 1721-1728
[73.]
B. Spellberg, T.J. Walsh, D.P. Kontoyiannis, J.E. Edwards Jr., A.S. Ibrahim.
Recent advances in the management of mucormycosis: from bench to bedside.
Clin Infect Dis, 48 (2009), pp. 1743-1751
[74.]
N. Singh, J.M. Aguado, H. Bonatti, G. Forrest, K.L. Gupta, N. Safdar, et al.
Zygomycosis in solid organ transplant recipients: a prospective matched case–control study to assess risks for disease and outcome.
J Infect Dis, 200 (2009), pp. 1002-1011
[75.]
A.S. Ibrahim, T. Gebremariam, Y. Fu, J.E. Edwards Jr., B. Spellberg.
Combination echinocandin-polyene treatment of murine mucormycosis.
Antimicrob Agents Chemother, 52 (2008), pp. 1556-1558
[76.]
C. Reed, R. Bryant, A. Ibrahim, J. Edwards Jr., S.G. Filler, R. Goldberg, et al.
Combination polyene–caspofungin treatment of rhino–orbital–cerebral mucormycosis.
Clin Infect Dis, 47 (2008), pp. 364-371
[77.]
J.A. Van Burik, R.S. Hare, H.F. Solomon, M.L. Corrado, D.P. Kontoyiannis.
Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases.
Clin Infect Dis, 42 (2006), pp. 61-65
[78.]
R.N. Greenberg, K. Mullane, J.A. Van Burik, I. Raad, M.J. Abzug, G. Anstead, et al.
Posaconazole as salvage therapy for zygomycosis.
Antimicrob Agents Chemother, 50 (2006), pp. 126-133
[79.]
A.S. Ibrahim, T. Gebremariam, J.A. Schwartz, J.E. Edwards Jr., B. Spellberg.
Posaconazole mono or combination therapy for treatment of murine zygomycosis.
Antimicrob Agents Chemother, 53 (2009), pp. 772-775
[80.]
A.S. Ibrahim, T. Gebermariam, Y. Fu, L. Lin, M.I. Husseiny, S.W. French, et al.
The iron chelator deferasirox protects mice from mucormycosis through iron starvation.
J Clin Invest, 117 (2007), pp. 2649-2657
[81.]
C. Reed, A. Ibrahim, J.E. Edwards Jr., I. Walot, B. Spellberg.
Deferasirox, an iron-chelating agent, as salvage therapy for rhinocerebral mucormycosis.
Antimicrob Agents Chemother, 50 (2006), pp. 3968-3969
[82.]
P. Troke, K. Aguirrebengoa, C. Arteaga, D. Ellis, C. Heath, I. Lutsar, et al.
Treatment of scedosporiosis with voriconazole: clinical experience with 107 patients.
Antimicrob Agents Chemother, 52 (2008), pp. 1743-1750
[83.]
K.J. Cortez, E. Roilides, F. Quiroz-Telles, J. Meletiadis, C. Antachopoulos, T. Knudsen, et al.
Infections caused by Scedosporium spp.
Clin Microbiol Rev, 21 (2008), pp. 157-197
[84.]
A. Alastruey-Izquierdo, M. Cuenca Eestella, A. Monzón, E. Mellado, J.L. Rodríguez-Tudela.
Antifungal susceptibility profile of clinical Fusarium spp. isolates.
J Antimicrob Chemother, 61 (2008), pp. 805-809
[85.]
M. Nucci, E. Anaissie.
Fusarium infections in immunocompromsied patients.
Clin Microbiol Rev, 30 (2007), pp. 695-704
[86.]
M. Stanzani, F. Tumietoo, N. Vianelli, M. Baccarani.
Update on the treatment of disseminated fusariosis: focus on voriconazole.
Ther Clin Risk Manage, 3 (2007), pp. 1165-1173
[87.]
L.J. Scott, D. Simpson.
Voriconazole: a review of its use in the management of invasive fungal infections.
Drugs, 67 (2007), pp. 269-278
[88.]
J. Guinea, T. Peláez, S. Recio, M. Torres-Narbona, E. Bouza.
In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species.
Antimicrob Agents Chemother, 52 (2008), pp. 1396-1400
[89.]
A.C. Pasqualotto, K.O. Thiele, L.Z. Goldani.
Novel triazole antifungal drugs: focus on isavuconazole, ravuconazole and albaconazole.
Curr Opin Investig Drugs, 11 (2010), pp. 165-174
[90.]
P.A. Warn, A. Sharp, G. Morrissey, D.W. Denning.
Activity of aminocandin (IP960; HMR3270) compared with amphotericin B, itraconazole, caspofungin and micafungin in neutropenic murine models of disseminated infection caused by itraconazole susceptible and resistant strains of Aspergillus fumigatus.
Int J Antimicrob Agents, 35 (2010), pp. 146-151
[91.]
J. Pachl, P. Svoboda, F. Jacobs, K. Vandewoude, B. Van der Hoven, P. Spronk, Mycograb Invasive Candidiasis Study Goup, et al.
A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis.
Clin Infect Dis, 42 (2006), pp. 1404-1413
Copyright © 2011. Elsevier España S.L.. Todos los derechos reservados
